$NVDA NEWS
Nvidia stock hits another record as Wall Street stays bullish
NasdaqGM - Delayed Quote USD
CRISPR Therapeutics AG (CRSP)
At close: 4:00 PM EDT
After hours: 5:03 PM EDT
Research Analysis
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 23 | 23 | 25 | 25 |
Avg. Estimate | -1.42 | -1.33 | -5.67 | -4.99 |
Low Estimate | -1.9 | -2.01 | -7.46 | -7.59 |
High Estimate | -0.43 | -0.1 | -3.96 | 5.05 |
Year Ago EPS | -1.41 | 1.1 | -1.94 | -5.67 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
No. of Analysts | 22 | 21 | 24 | 25 |
Avg. Estimate | 6.81M | 31.88M | 48.79M | 279.98M |
Low Estimate | -- | -- | 1.02M | -- |
High Estimate | 75M | 455.7M | 458.9M | 3.31B |
Year Ago Sales | 7.96M | 201.21M | 371.21M | 48.79M |
Sales Growth (year/est) | -14.40% | -84.20% | -86.90% | 473.80% |
Earnings History
CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
---|---|---|---|---|
EPS Est. | -1.95 | -0.07 | -1.33 | -1.52 |
EPS Actual | -1.41 | 1.1 | -1.43 | -1.49 |
Difference | 0.54 | 1.17 | -0.1 | 0.03 |
Surprise % | 27.70% | 1,671.40% | -7.50% | 2.00% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Current Estimate | -1.42 | -1.33 | -5.67 | -4.99 |
7 Days Ago | -1.42 | -1.31 | -5.69 | -4.96 |
30 Days Ago | -1.42 | -1.31 | -5.68 | -4.95 |
60 Days Ago | -1.4 | -1.29 | -5.68 | -4.99 |
90 Days Ago | -1.4 | -1.33 | -5.63 | -4.53 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
---|---|---|---|---|
Up Last 7 Days | 1 | -- | 1 | 1 |
Up Last 30 Days | 1 | -- | 1 | 1 |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
CURRENCY IN USD | CRSP | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | -0.70% | -- | -- | 3.60% |
Next Qtr. | -220.90% | -- | -- | 7.90% |
Current Year | -192.30% | -- | -- | 2.50% |
Next Year | 12.00% | -- | -- | 13.10% |
Next 5 Years (per annum) | -200.40% | -- | -- | 11.87% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
Maintains | RBC Capital: Sector Perform to Sector Perform | 10/4/2024 |
Maintains | Truist Securities: Buy to Buy | 8/12/2024 |
Reiterates | Cantor Fitzgerald: Neutral | 8/8/2024 |
Maintains | Barclays: Equal-Weight to Equal-Weight | 8/6/2024 |
Maintains | RBC Capital: Sector Perform to Sector Perform | 8/6/2024 |
Maintains | Stifel: Hold to Hold | 8/6/2024 |
Related Tickers
NTLA Intellia Therapeutics, Inc.
20.67
-1.94%
BEAM Beam Therapeutics Inc.
23.15
-2.11%
EDIT Editas Medicine, Inc.
3.7600
+11.90%
VRTX Vertex Pharmaceuticals Incorporated
478.09
-1.02%
RXRX Recursion Pharmaceuticals, Inc.
6.76
-2.59%
MRNA Moderna, Inc.
53.80
-0.55%
VKTX Viking Therapeutics, Inc.
64.34
-2.22%
AXSM Axsome Therapeutics, Inc.
91.50
-1.98%
DNA Ginkgo Bioworks Holdings, Inc.
8.92
+0.45%
BLUE bluebird bio, Inc.
0.4968
+1.22%